<ѻýҕl>CAR-T Drives High Response in Relapsed/Refractory ALLѻýҕl> ZUMA-3 study shows brexucabtagene autoleucel offers long-term clinical benefit Jun 06, 2021
<ѻýҕl>Combination Therapy Achieves High Response in Ph+ ALLѻýҕl> Ponatinib-blinatumomab offers promising regimen in frontline and relapse/refractory disease Jun 05, 2021
<ѻýҕl>Combo Therapy Boosts Response in Hairy Cell Leukemiaѻýҕl> Complete response achieved in 26 of 30 patients with vemurafenib/rituximab May 12, 2021
<ѻýҕl>Op-Ed: Blood Cancer Patients Need More COVID Vax Answersѻýҕl> Patients are left wondering, "will I be protected?" Mar 24, 2021
<ѻýҕl>Whole-Genome Sequencing Makes a Case in Leukemia Studyѻýҕl> More actionable alterations detected in myeloid malignancies versus cytogenetics Mar 10, 2021
<ѻýҕl>Study Confirms Risk-Adapted CRS Prophylaxis for Acute Leukemiaѻýҕl> Tocilizumab reduced severe cytokine release syndrome in children, young adults Mar 09, 2021
<ѻýҕl>Blincyto Shines for Kids' B-Cell ALLѻýҕl> Overall survival boost seen in new trials Mar 05, 2021
<ѻýҕl>Ethics Consult: Refuse Treatment for Dictator? MD/JD Weighs Inѻýҕl> You voted, now see the results and an expert's discussion Jan 15, 2021
<ѻýҕl>PARP Inhibitors Linked With Blood Cancer Riskѻýҕl> Incidence of MDS/AML under 1%, but further investigation warranted as indications broaden Dec 28, 2020
<ѻýҕl>Chemo-Free Combo Boosts PFS in First-Line CLLѻýҕl> PI3K-delta-based regimen also topped chemoimmunotherapy in relapsed setting Dec 08, 2020
<ѻýҕl>Novel Agent Active in Refractory CMLѻýҕl> Asciminib doubles molecular response versus bosutinib after two or more prior lines of therapy Dec 08, 2020
<ѻýҕl>Fixed-Duration Ibrutinib-Venetoclax Promising in First-Line CLLѻýҕl> DFS at 1 year reaches 95% in patients with undetectable MRD Dec 06, 2020
<ѻýҕl>Blood Cancers and COVID-19: 'A Medically Vulnerable' Groupѻýҕl> Patients with hematologic malignancies and SARS-CoV-2 face higher risks for infection, death Dec 06, 2020
<ѻýҕl>These Forbes 400 Billionaires Made Their Fortunes in Healthcareѻýҕl> 14 individuals, $66 billion in combined net worth Sep 24, 2020
<ѻýҕl>Raising the Bar for Myelofibrosis Therapy Developmentѻýҕl> Rational combinations, new targets, and a first-ever phase III trial with a survival endpoint Sep 14, 2020
<ѻýҕl>Worse Blood Cancer Outcomes in Hispanicsѻýҕl> Diagnosis at earlier age, worse survival, especially for those on U.S.-Mexico border Jun 24, 2020
<ѻýҕl>Combination Ups Survival in Older AML Patientsѻýҕl> Frontline venetoclax plus azacitidine adds 5 months to median OS versus azacitidine alone Jun 17, 2020
<ѻýҕl>Early Palliation: Boon for AML Patients on Intensive Chemoѻýҕl> Intervention led to marked improvements in QoL, mental distress, end-of-life care Jun 02, 2020
<ѻýҕl>COVID-19 Mortality Spikes in Patients With Lung, Blood Cancersѻýҕl> Those with metastatic disease also at special risk for poor outcomes Apr 28, 2020
<ѻýҕl>DOAC Works in Cancer-Related VTE, No Tradeoff in Bleedsѻýҕl> Apixaban monotherapy matches dalteparin in non-inferiority trial Mar 29, 2020
<ѻýҕl>Bringing Transplant to More Patients With AMLѻýҕl> Conditioning with radiolabeled antibody leads to successful transplantation in 84% of older patients Feb 25, 2020
<ѻýҕl>New CAR-T Makes Case for Aggressive Lymphomasѻýҕl> Largest trial to date shows 73% ORR, 53% CR, potential for outpatient treatment Feb 25, 2020
<ѻýҕl>Stem-Cell Transplant Trial Ends in a Drawѻýҕl> Similar PFS with haploidentical bone marrow, double unrelated umbilical cord blood Feb 24, 2020
<ѻýҕl>Myeloablative Therapy Prevails in AML Transplant Studyѻýҕl> Better survival, fewer relapses compared with reduced-intensity conditioning Feb 21, 2020
<ѻýҕl>Better Quality CR With One AML Therapy vs Another?ѻýҕl> Longer survival after CR/CRi with CPX-351 than with 7+3 in patients with AML-MRC Feb 21, 2020
<ѻýҕl>Gains in Stem Cell Transplant Mortality Over Last 25 Yearsѻýҕl> But outcomes still "far from perfect" Jan 20, 2020
<ѻýҕl>Higher Risk of Shingles Seen in Patients With Certain Cancersѻýҕl> Vaccine development may help with prevention of herpes zoster in this population Dec 31, 2019
<ѻýҕl>Survival Bump With Oral AML Maintenanceѻýҕl> Ten-month OS gain, doubling of RFS with oral azacitidine in transplant-ineligible patients Dec 10, 2019
<ѻýҕl>IGHV-Unmutated CLL: Gene Signature May Predict Outcomes After First-Line FCRѻýҕl> Prognostic tool may predict who is likely to achieve a relatively long remission Oct 15, 2019
<ѻýҕl>FCR Still an Option in IGHV-Unmutated CLL?ѻýҕl> Gene signature identifies lower-risk group with greater chemoimmunotherapy benefit Oct 08, 2019
<ѻýҕl>Ibrutinib's Cardiotoxicity Comes Into Focusѻýҕl> Study identifies new cardiac events linked to so-called targeted therapy Sep 25, 2019
<ѻýҕl>Overall Survival Data in for Gilteritinib as AML Salvage Txѻýҕl> FLT3 Inhibitor tops chemotherapy in randomized trial Apr 01, 2019
<ѻýҕl>Transplant No Help in Hypodiploid ALLѻýҕl> Similar 5-year outcomes with or without HSCT, regardless of MRD status Mar 29, 2019
<ѻýҕl>Are Patients Better Off With Image-Guided Bone Marrow Biopsy?ѻýҕl> Prospect of sedation has some going to interventional radiology Mar 29, 2019
<ѻýҕl>Increased Risk of Chemo-Associated AML for Nearly All Solid Cancersѻýҕl> Extended beyond 5 years for most types with greater risk seen in young patients Dec 20, 2018
<ѻýҕl>Higher Risk of Shingles Seen in Patients With Certain Cancersѻýҕl> Vaccine development may help with prevention of herpes zoster in this population Dec 14, 2018
<ѻýҕl>ASH Poster Rounds: Obesity Impacts CLL Survival in Womenѻýҕl> Plus: New risk model predicts CLL survival; novel BTK inhibitor works after ibrutinib Dec 06, 2018
<ѻýҕl>Chemo-Free Tx Tops Best Option in Younger CLL Patientsѻýҕl> Improved overall survival and safety with ibrutinib-based therapy Dec 04, 2018
<ѻýҕl>Add-On Drugs Could Boost Efficacy, Tolerability of CAR T-Cell Therapiesѻýҕl> Studies test addition of targeted agents, immunotherapy Dec 03, 2018
<ѻýҕl>CAR T-Cell Responses Prove Durable in ALL, DLBCLѻýҕl> Two studies demonstrate long-term control in relapsed/refractory disease Dec 01, 2018